GSE183113 sorafenib 1 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE183113_sorafenib_1_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE183113_sorafenib_1_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE183113_sorafenib_1_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE183113_sorafenib_1_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

uncharacterized LOC105377557

Gene

HTT antisense RNA

Gene

uncharacterized LOC101927827

Gene

cancer susceptibility 17

Gene

BCR pseudogene 8

Gene

RNA, 7SL, cytoplasmic 517, pseudogene

Gene

ribosomal protein L35a pseudogene 14

Gene

olfactory receptor family 1 subfamily F member 12, pseudogene

Gene

formyl peptide receptor 3

Gene

beta-1,4-N-acetyl-galactosaminyltransferase 4

  • Gene

    uncharacterized LOC105377557


  • Gene

    HTT antisense RNA


  • Gene

    uncharacterized LOC101927827


  • Gene

    cancer susceptibility 17


  • Gene

    BCR pseudogene 8


  • Gene

    RNA, 7SL, cytoplasmic 517, pseudogene


  • Gene

    ribosomal protein L35a pseudogene 14


  • Gene

    olfactory receptor family 1 subfamily F member 12, pseudogene


  • Gene

    formyl peptide receptor 3


  • Gene

    beta-1,4-N-acetyl-galactosaminyltransferase 4

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.